☆ 4.5 Article

Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up

EPILEPSIA (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Clinical Neurology

CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment

William Hong et al.

Summary: Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental and epileptic encephalopathy with infantile-onset epilepsy. The management of seizures in CDD is challenging due to their highly refractory nature and limited evidence-based treatment options.

CNS DRUGS (2022)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Elia M. Pestana Knight et al.

Summary: This study evaluated the efficacy and safety of ganaxolone in patients with CDKL5 deficiency disorder (CDD) and refractory epilepsy. The results showed that ganaxolone significantly reduced seizure frequency in CDD patients and was generally well tolerated. The study suggests a potential treatment benefit for ganaxolone in CDD and further long-term treatment is being assessed in the ongoing open-label extension phase.

LANCET NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

CDKL5 deficiency disorder: clinical features, diagnosis, and management

Helen Leonard et al.

Summary: CDKL5 deficiency disorder (CDD) is a developmental epileptic encephalopathy characterized by early-onset seizures, severe developmental impairment, and common gastrointestinal, sleep, and musculoskeletal problems. It has a higher prevalence of cerebral visual impairment compared to other developmental epileptic encephalopathies. Currently, there is limited evidence regarding effective treatment for CDD, but further treatment trials are underway.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

CDKL5 deficiency disorder in males: Five new variants and review of the literature

Barbara Siri et al.

Summary: CDKL5 Deficiency Disorder (CDD) is an X-linked dominant disease characterized by early-onset epileptic encephalopathy and developmental delay, with males showing severe developmental delay, cortical visual impairment, and early-onset refractory epilepsy. Germ-line truncating CDKL5 variants are the most recurrent mutations in CDD, leading to a worsen phenotype. Post-zygotic CDKL5 mosaicism may result in milder phenotypes and variable response to antiepileptic treatments in some subjects.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder

Heather E. Olson et al.

Summary: The treatment for neurological features of CDD is currently symptom-based and empirical, not specific to CDD. Anti-seizure medications are commonly used, with ketogenic diet also being a common treatment approach. There is limited information on medications for sleep, behavioral management, and movement disorders, highlighting the need for further research in these areas.

JOURNAL OF NEURODEVELOPMENTAL DISORDERS (2021)

添加到收藏夹

Article Neurosciences

CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy

Martyna Jakimiec et al.

BRAIN SCIENCES (2020)

添加到收藏夹

Article Clinical Neurology

Comparison of Core Features in Four Developmental Encephalopathies in the Rett Natural History Study

Clare Cutri-French et al.

ANNALS OF NEUROLOGY (2020)

添加到收藏夹

Article Developmental Biology

Molecular and Synaptic Bases of CDKL5 Disorder

Yong-Chuan Zhu et al.

DEVELOPMENTAL NEUROBIOLOGY (2019)

添加到收藏夹

Review Clinical Neurology

Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review

Heather E. Olson et al.

PEDIATRIC NEUROLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Analysis of the Phenotypes in the Rett Networked Database

Elisa Frullanti et al.

INTERNATIONAL JOURNAL OF GENOMICS (2019)

添加到收藏夹

Article Clinical Neurology

Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort

Joseph D. Symonds et al.

BRAIN (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

3β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield

Shu-Hui Chuang et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)

添加到收藏夹

Article Clinical Neurology

Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy

A. Mueller et al.

EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2016)

添加到收藏夹

Article Clinical Neurology

Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder

Stephanie Fehr et al.

NEUROLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy

Stephanie Fehr et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.